International Clinical Trial: Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07807449) titled 'Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older' on Sept. 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Yikang Biotech (Suzhou) Co., Ltd.

Condition: Respiratory Syncytial Virus (RSV)

Intervention: Biological: Recombinant RSV Vaccine (CHO Cell) Biological: Recombinant RSV Vaccine (CHO Cell) Biological: Adjuvant Suspension Biological: Recombinant RSV Vaccine (CHO ...